Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Key Points
Key Points
- Multiple studies of both chemotherapy and endocrine therapy have shown that neoadjuvant treatment can increase the likelihood of breast-conserving surgery.
- The CTNeoBC pooled analysis of neoadjuvant breast cancer clinical trials published in 2014 confirmed that achievement of a pathologic complete response (pCR) with neoadjuvant treatment was prognostic.
- It also showed that the association between pCR and outcomes was strongest in patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease.
- Optimal therapy for breast cancer is driven by subtype.
Treatment
...reatme...
...tion from 2022 Guideline Rapid Rec...
...th T1cN1-2 or T2-4N0 (stage II or III), early-st...
...andidat...
...vant chemotherapy is the treatment of choice...
...umor histology, grade, stage and estrogen, proges...
Neoadjuvant systemic therapy should be of...
...adjuvant systemic therapy may be offer...
...r whom a delay in surgery is preferable...
Measuring Response
...asuring Respon...
...atients receiving neoadjuvant therapy should be...
...d- and tissue-based biomarkers should not be...
...efined as absence of invasive dise...
Recommended Regimens for Patients with TNBC
...mmended Regimens for Patients with TNBC...
...TNBC who have clinically node positive and/o...
...th cT1a or cT1bN0 TNBC should not...
...be offered as part of a neoadjuvant re...
...is insufficient evidence to recommend routin...
Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
Recommended Neoadjuvant Treatment for Pati...
...hemotherapy can be used instead of...
...or postmenopausal patients with HR+, HER2-negative...
For premenopausal patients with HR+, HER2-...
Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease
...oadjuvant Treatment for Patients with H...
...de-positive or high-risk node-negative, HER...
...T1a N0 and T1b N0, HER2+ disease should not b...